Key Highlights
- ARK Invest acquired approximately 281,000 shares of CRSP valued at roughly $14.82M following a 10% price decline
- CRISPR Therapeutics announced a $350M private placement that triggered the market selloff
- The gene-editing company represents ARK’s second-largest position across all ETFs, totaling approximately $500M in exposure
- ARK reduced holdings in 10x Genomics (TXG) and Teradyne (TER) during portfolio rebalancing
- Both Seeking Alpha Quant and Wall Street analysts maintain Buy ratings on CRSP
Shares of CRISPR Therapeutics (CRSP) declined approximately 10% following the company’s announcement of a $350M private placement. Cathie Wood’s ARK Invest responded by adding to its position during the price weakness.
The investment firm accumulated approximately 281,000 shares of CRSP distributed across its ETF lineup, representing a total investment of about $14.82M. ARK disclosed these transactions in its daily trading report dated March 11, 2026.
This purchase extends a pattern established in recent quarters. During Q4 2025, Wood expanded ARK’s CRSP holdings by 7.5%, accumulating around 735,000 additional shares. The recent acquisition maintains that bullish trajectory.
CRSP currently stands as ARK’s second-largest holding when measured across all combined ETFs, representing a 4.49% portfolio weight and approximately $500M in aggregate exposure. This represents substantial conviction in a company still working toward consistent revenue generation.
Private Placement Triggers Selloff
The share price decline followed CRISPR Therapeutics‘ announcement of a $350M private placement. These capital raises typically create dilution for current shareholders, which often results in immediate downward pressure on the stock price.
The capital infusion aligns with the company’s current operational stage. CRISPR Therapeutics operates without revenue and maintains negative operating margins, making periodic fundraising essential for advancing its development pipeline.
The company maintains a robust financial foundation — featuring a current ratio of 13.32 and a debt-to-equity ratio of 0.11, indicating substantial liquidity paired with minimal debt obligations.
This strong financial positioning appears to have supported ARK’s decision to increase exposure during the price decline.
Pipeline and Product Development
CRISPR Therapeutics received approval for its initial product, Casgevy, developed in partnership with Vertex Pharmaceuticals. The treatment addresses sickle-cell disease and transfusion-dependent beta-thalassemia.
The company’s development pipeline extends beyond Casgevy, encompassing programs focused on immuno-oncology, cardiovascular disease, and stem cell-derived treatments for Type 1 diabetes.
Current market capitalization stands at approximately $5.07 billion based on recent valuations.
Insider transaction data shows a clear trend over the past three months — five separate selling transactions totaling 163,751 shares, with no recorded insider purchases during this period.
Portfolio Adjustments Across ARK ETFs
While increasing its CRSP position, ARK decreased exposure elsewhere in its portfolio. The firm sold 78,412 shares of 10x Genomics (TXG) valued at approximately $1.60M and divested 21,505 shares of Teradyne (TER) worth $6.47M.
These transactions align with standard portfolio management practices across ARK’s actively managed ETF structure rather than indicating specific concerns about those companies.
Analyst sentiment toward CRSP remains favorable. Both Seeking Alpha’s Quant rating system and Wall Street analysts assign Buy ratings to the stock. The Quant analysis highlights particular strength in growth and momentum metrics.
A Seeking Alpha analyst emphasized Casgevy’s market introduction and the company’s cash position as primary strengths, while acknowledging the inherent uncertainties associated with pre-revenue biotechnology companies.
GuruFocus’ GF Value metric currently assesses CRSP as significantly overvalued, assigning a GF Value of $16.13, which contrasts with the prevailing bullish analyst outlook.
CRSP shares declined approximately 10.17% on the trading day when the private placement was announced.
